← #nieuws

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

,

ProQR has received a Fast Track designation from the Food and Drug Administration (FDA) for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need. It was established with the intention to bring promising drugs to patients sooner by facilitating the development with more frequent FDA interactions and expediting the review process.

“We are very pleased with the Fast Track designation the FDA granted us for QR-421a. Patients with Usher syndrome, the leading cause of combined deafness and blindness, currently have no available therapies for their vision loss and this designation emphasizes the high unmet need in this disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in the Phase 1/2 STELLAR clinical trial in the coming months with preliminary data expected in mid-2019.”

Source: ProQR

← #nieuws

Bristol-Myers Squibb acquires Celgene

Bristol-Myers Squibb and Celgene have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.

Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene. Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.

The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. With complementary areas of focus, the combined company will operate with global reach and scale, maintaining the speed and agility that is core to each company’s strategic approach.

Based on the closing price of Bristol-Myers Squibb stock of $52.43 on January 2, 2019, the cash and stock consideration to be received by Celgene shareholders at closing is valued at $102.43 per Celgene share and one CVR (as described below). When completed, Bristol-Myers Squibb shareholders are expected to own approximately 69 percent of the company, and Celgene shareholders are expected to own approximately 31 percent.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation. We will also benefit from an expanded early- and late-stage pipeline that includes six expected near-term product launches. Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.”

Dr. Caforio continued, “We are impressed by what Celgene has accomplished for patients, and we look forward to welcoming Celgene employees to Bristol-Myers Squibb. Our new company will continue the strong patient focus that is core to both companies’ missions, creating a shared organization with a goal of discovering, developing and delivering innovative medicines for patients with serious diseases. We are confident we will drive value for shareholders and create opportunities for employees.”

“For more than 30 years, Celgene’s commitment to leading innovation has allowed us to deliver life-changing treatments to patients in areas of high unmet need. Combining with Bristol-Myers Squibb, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company,” said Mark Alles, Chairman and Chief Executive Officer of Celgene. “Our employees should be incredibly proud of what we have accomplished together and excited for the opportunities ahead of us as we join with Bristol-Myers Squibb, where we can further advance our mission for patients. We look forward to working with the Bristol-Myers Squibb team as we bring our two companies together.”

Approvals and Timing to Close

The transaction is subject to approval by Bristol-Myers Squibb and Celgene shareholders and the satisfaction of customary closing conditions and regulatory approvals. Bristol-Myers Squibb and Celgene expect to complete the transaction in the third quarter of 2019.

Source: Celgene

← #nieuws

DegenRx secures funding for Alzheimer’s disease gene therapy

DegenRx, a biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases, has secured financing for their antibody-based gene therapy program for the treatment of Alzheimer’s disease (AD).

Participating in this Series A financing are Swanbridge Capital and BOM Brabant Ventures, together with several private investors seasoned in the pharma and biotech industry. The company will be managed by Guus Scheefhals as Chief Executive Officer and Hans Preusting as Chief Development Officer. DegenRx aims to develop vector-based gene therapies for degenerative brain disorders, such as Alzheimer’s and Parkinson’s disease. Gene therapy aims to provide a potentially lifelong effect after a single administration. DegenRX will develop its proprietary, highly specific antibody, targeting and neutralizing toxic Alzheimer proteins in the brain that would thus slow down or ideally stop disease progression. The current funding will be used to demonstrate the feasibility of this approach in a pre-clinical model.

 Guus Scheefhals, CEO of DegenRx, commented: “We are very pleased that the investors are prepared to take on this early opportunity. Degenerative diseases are having an increasing impact on society and most still lack disease-modifying treatments. This investment enables us to show that our innovative approach can work. By making the active compound in the brain, we avoid the need to pass the blood-brain barrier which is typically a significant hurdle for most drugs and certainly for the larger ones, such as antibodies. We are very excited about the potential of our program and hope it will ultimately contribute to the urgently needed benefit for AD patients.”

Nicky Rijk-Vogels, fund manager at Swanbridge Capital: “In terms of phase and technology, DegenRx fits perfectly with the mission of Swanbridge Capital. Our goal is to ensure that young biotech companies can take the next step by providing them with the necessary venture capital and relevant support. We believe in the potential of gene therapy and are happy to contribute to the broader application that DegenRx has in mind for the treatment of degenerative brain diseases. ”

Mercedes Tuin, Investment Manager Life Sciences & MedTech at BOM Brabant Ventures: “BOM Brabant Ventures invests in Brabant companies that have the potential to become disruptive world players. DegenRx has that potential. With Guus Scheefhals and Hans Preusting as Chief Development Officer on board, we have every confidence that the DegenRx team will succeed in their mission.”

Source: DegenRx press release

← #nieuws

Xenikos will conduct Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

,

Xenikos has partnered with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 registration trial to test the efficacy of T-Guard in treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following an allogeneic stem cell transplant. Funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute, both part of the National Institues of Health, the BMT CTN includes leading transplant centers in the United States (U.S.) and will provide a total of USD 1.37 million in funding for the T-Guard trial.

“At Xenikos, we see BMT CTN’s access to major transplant centers in the U.S., as well as their established track record for successfully recruiting patients with acute GVHD, and vast knowledge and expertise in this field, as aiding in the development of innovative new immunotherapies for improving patient outcomes” said Dr. Ypke van Oosterhout, CEO of Xenikos. “We are therefore confident that our partnership with BMT CTN will help bring T-Guard to transplant patients as quickly as possible.”

“Our network often conducts large, multi-institutional clinical trials in order to test new treatments designed to improve outcomes associated with hematopoietic stem cell transplantation or HSCT,” said Dr. Mehdi Hamadani of the BMT CTN. “Acute GVHD is a life-threatening complication of HSCT and better treatments are needed for our patients. The preliminary data obtained with T-Guard is quite promising, and we believe that the Phase 3 trial is the next logical step.”

The U.S.-based Phase 3 trial will be a multi-center study involving patients who have received an allogeneic stem cell transplant for a myeloid or lymphoid malignancy and subsequently developed SR-aGVHD. Importantly, the Phase 3 trial design is based on input received from the U.S. Food and Drug Administration at the End-of-Phase 2 meeting. Xenikos plans to file an Investigational New Drug application in 2019.

← #nieuws

Enpicom sets a new standard for B cell receptor repertoire analysis

,

The Dutch bioinformatics software engineering company ENPICOM announced that they have finalized development and released an expanded version of their ImmunoGenomiX (IGX) platform to support discovery and development of novel immunotherapies, patient stratification for, and treatment monitoring of immunotherapies. IGX now also accepts B cell receptor (BCR) in addition to T cell receptor (TCR) sequencing data. Head-to-head benchmarking studies versus world’s most popular tool, pRESTO, show superiority on several levels.

The improvements in high-throughput sequencing (HTS) technology provide unprecedented opportunities to explore the enormous diversity of the immune repertoire by deep sequencing T cell receptors and B cell receptors. However, an efficient, integrated, easy-to-use and accurate analytical tool required to process the huge amounts of immunosequencing data has so far been lacking.

With the IGX platform, ENPICOM is on a mission to provide the immunotherapy community with a best-in-class solution to analyze T cell and B cell receptor (TCR/BCR) immunosequencing data. The base module of the IGX platform to perform T cell receptor repertoire analysis, IGX Explore, was launched in August this year. The current functional expansion of IGX Explore adds support for the identification and quantification of B cell receptors (BCRs) from HTS data. Dr. Nicola Bonzanni, ENPICOM’s Chief Scientific Officer, commented: “As BCR analysis harbors additional complexities, such as immunoglobulin (Ig) (i.e. antibody) gene somatic hypermutations, the development of a state-of-the-art solution for Ig/BCR sequence analysis offered more extensive challenges for our bioinformatics and software engineering teams. It is with great pleasure that we announce the timely release of the next version of IGX Explore and that our benchmarking studies showed even better performance than expected.”

Dr. Bonzanni continues: “We benchmarked the performance of IGX Explore for BCRs using both synthetic and experimental datasets. IGX Explore shows superior performance for critical metrics such as correctly identified CDR3 sequences and V/J gene identification. Specifically, we compared IGX Explore with pRESTO (Vander Heiden, et al. 2014), the world’s most popular BCR sequencing analysis tool. On synthetic data, we show that IGX Explore achieves consistent and highly precise performance across all commonly used read lengths, and outperforms pRESTO at short reads lengths in particular, as visualized in the graphs below.

Furthermore, using an independently published experimental dataset (Meng W, et al. 2017), we showed that IGX Explore is able to recapitulate the reference immune repertoire composition with high accuracy. Finally, IGX Explore outperforms pRESTO with regards to speed and scalability”.

As announced before, the ImmunoGenomiX (IGX) platform will be modularly expanded to become a comprehensive end-to-end immunosequencing data analysis platform designed to analyze, monitor, and compare immune repertoires in the context of immunotherapy development and at all stages of treatment and disease over time. Starting from high-throughput sequencing data, it will deliver an easy-to-read report appropriate for the specific application, be it research, diagnosis, patient stratification, or treatment monitoring. The IGX platform will allow customers to select their own sample preparation protocols and the HTS technology of choice. It requires no programming skills as the interface is intuitive and flexible.

The complete base module, IGX Explore, is now available and can perform clonality analysis of both TCR and BCR repertoires starting from raw sequencing data, report back the number of individual TCR/BCR clones and interactively visualize them in a user-friendly way. With IGX Explore, immunotherapy companies can boost their target discovery, research and drug development processes. Tailored software extensions to answer specific research or clinical questions can be custom-built in collaboration with ENPICOM’s team of immunologists and bioinformaticians.

Using a recently published and independent benchmark, ENPICOM showed in August that IGX Explore offered superior accuracy on TCRs and the current benchmark studies complement this picture for BCRs. More information about these benchmark studies can be found at the company’s website and will be published in a white paper shortly.

Source: ENPICOM

← #nieuws

Staten Biotechnology and Novo Nordisk collaboration on novel treatment for dyslipidaemia

,

Staten Biotechnology and Novo Nordisk announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.

Under the collaboration agreement, Novo Nordisk will provide research and development (R&D) funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia.

“Novo Nordisk is joining forces with Staten Biotechnology at an exciting time for us, with the company’s lead compound moving towards its first clinical trial, aiming to address the residual cardiovascular risk in patients with hypertriglyceridaemia,” said Dr Hilde Steineger, CEO of Staten Biotechnology. “This partnership provides the company not only with a knowledgeable development partner but also with a funding structure that allows founders, management and the founding investors to accelerate the development of company”.

“Our partnership with Staten Biotechnology is a key step in executing our strategic priority to expand into cardiovascular diseases. Hypertriglyceridemia is a serious risk factor for cardiovascular disease, in particular often present in people with diabetes and obesity. Staten Biotechnology has developed STT-5058, a new promising concept validated by human genetics, for the treatment of hypertriglyceridemia. Combining Staten’s know-how on STT-5058, the scientific excellence of the company’s executive team and founders, with Novo Nordisk experience in drug development and commercialization, the project holds potential to make a real difference for people suffering from cardiovascular disease,” said Marcus Schindler, Senior Vice President, Global Drug Discovery in Novo Nordisk.

Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will potentially receive signing and exercise fees, R&D funding, and milestone payments of up to 430 million euros.

Source: Staten Biotechnology

← #nieuws

Minister Wiebes zet belang vestigingsklimaat op de kaart

,

Dinsdag verscheen een mooie brief van Minister Wiebes van Economische Zaken en Klimaat over de bijdrage van buitenlandse bedrijven aan de Nederlandse economie. Daarin besteedt Wiebes veel aandacht aan het belang van gerichte acquisitie van bedrijven die de Nederlandse kennispositie verder versterken, met daarin een prominente rol voor de life sciences.

De aantrekkelijkheid van Nederland voor investeringen van buitenlandse bedrijven hangt niet alleen af van goede acquisitie, maar staat of valt met een sterk vestigingsklimaat. Minister Wiebes geeft aan dat de overheid hierin moet blijven investeren omdat dat ten goede komt van alle bedrijven, klein en groot, die in Nederland ondernemen. Eén van de elementen daarin richt zich op de gaten in het financieringslandschap, waar Wiebes mogelijkheden ziet voor Invest-NL. Ook haalt de minister extra investeringen in onderwijs aan die moeten zorgen voor voldoende beschikbaarheid van geschikt personeel, nu en in de toekomst.

Lees de hele brief hier

← #nieuws

Innovatiekrediet klinische ontwikkeltrajecten omhoog naar € 30 miljoen

,

Voor een ijzersterk innovatieklimaat zijn voldoende financieringsmogelijkheden in de verschillende fases van ontwikkeling onontbeerlijk. HollandBIO maakt zich daarom hard voor een betere beschikbaarheid van financiering voor start-ups en scale-ups. Het is dan ook een flinke opsteker dat het budget voor klinische ontwikkeltrajecten met € 10 miljoen is opgehoogd tot € 30 miljoen. Een mooi resultaat waar HollandBIO zich jarenlang voor heeft ingezet. Het totale budget voor het Innovatiekrediet voor 2019 komt daarmee uit op € 60 miljoen.

 

Begin 2018 werd bekend dat het budget voor klinische projecten al op 1 januari flink was overvraagd. Het is daarom raadzaam om aanvragen op 1 januari 2019 in te dienen. Voor het in behandeling nemen van aanvragen is de dag van ontvangst van de aanvraag bepalend, en niet het tijdstip. Daarnaast is het belangrijk dat de aanvraag voor een Innovatiekrediet volledig wordt ingediend. Zie voor alle informatie over het Innovatiekrediet de website van RVO.

Gaten in financieringslandschap

Het financieringslandschap voor life sciences bedrijven vertoont nog flinke gaten. HollandBIO maakt zich binnen het programma ‘Een ijzersterk innovatieklimaat’ onder andere hard voor betere beschikbaarheid van kapitaal voor start-ups en scale-ups. We zien daarbij kansen voor de life sciences binnen de nieuw op te richten financieringsinstelling Invest-NL. Meer informatie vind je op onze website.

Zie ook:

https://www.hollandbio.nl/programmas/ijzersterk-innovatie-klimaat/

https://www.hollandbio.nl/nieuws/budgetuitputting-klinische-projecten-innovatiekrediet/

← #nieuws

Hudson River Biotechnology opens up new laboratory

,

Following the global surge in CRISPR investments and research, Hudson River Biotechnology (HRB) is pleased to announce the opening of its new 150m2 laboratory. As one of the few European companies fully dedicated to gene-editing and precision plant breeding, HRB is pleased to take this next important step in the evolution of the company and strengthen the agricultural R&D eco-system in Europe.

HRB is a young and highly innovative agricultural biotech company located in Wageningen. HRB applies novel breeding techniques such as CRISPR to develop new plant traits and has exclusive access to a novel genetic target identification platform, called SuRE (licensed from Amsterdam-based partner company Gen-X). HRB genetically optimizes crops to increase yields, improve disease resistance & nutritional value. The company has an internal R&D pipeline for development of novel platform technologies and varieties with new traits.

In addition, HRB uses their molecular breeding and target identification expertise to accelerate breeding efforts in co-development with plant breeders, seed companies and natural ingredient producers of all sizes. Combined, these efforts ultimately contribute to solving global food challenges such as the need for improved nutritional value or reduced pesticide use.

“We look forward to continue the rapid expansion of our company through this new lab” says Rudi Ariaans, CEO and HRB co-founder. Ferdinand Los, CSO and co-founder, adds “the new facility is fully equipped for the range of activities required for our R&D program”. In the new laboratory, HRB can deploy a range of activities in plant tissue and protoplast culture, genetics (DNA and RNA work), and protein biology. This enables HRB to effectively perform all the required steps in, for example, a CRISPR project, including discovery of genetic targets, in-house production of CRISPR proteins and guide RNAs, plant transfection and regeneration, and genetic testing.

Source: Hudson River Biotechnology

← #nieuws

Bio-based innovaties versnellen in Delft

,

Biotech Campus Delft stelt zich open voor derden

 

Er bestaan ambitieuze plannen voor de Biotech Campus Delft. Op het terrein van DSM is een  enthousiast team druk bezig de campus uit te bouwen tot Europa’s toonaangevende campus voor industriële biotechnologie. Locatiedirecteur Fedde Sonnema: “Nu al werken hier meer dan duizend mensen aan duurzame, ‘bio-based’ oplossingen voor voeding, diervoeding, biobrandstoffen en bioplastics. Vierhonderd onderzoekers kijken dagelijks hoe we de wereld kunnen voorzien van duurzame en nuttige producten. Door de locatie open te stellen voor derden en de uitwisseling van kennis en faciliteiten te stimuleren, ontstaat er een innovatiebroedplaats waarin we de transitie naar een ‘bio-based economy’ kunnen realiseren.”

 

Wisselwerking met TU Delft

Daarbij werkt DSM goed samen met de TU Delft, vertelt Sonnema. “DSM kan en wil het niet alleen doen. Een voortrekkersrol nemen we wel graag op ons. Dat doen we bijvoorbeeld door te investeren in laboratorium- en kantoorruimte en gemeenschappelijke voorzieningen. We delen kennis met nieuwkomers op de locatie. Wisselwerking met de TU Delft, die hier bijvoorbeeld cursussen en activiteiten organiseert of biotech start-ups tot wasdom kan laten komen, is daarbij essentieel. Dat geldt ook voor de inzet van lokale en provinciale overheden. Voor iedereen zijn het gemeenschappelijke belang en de kans die de Biotech Campus Delft biedt duidelijk: de regio uitbouwen als het Europese zenuwcentrum voor industriële biotechnologie.

 

Toegang tot innovatie ecosysteem

“Samenwerking tussen overheid, universiteit en industrie is doorslaggevend voor succes”, beaamt ook Cindy Gerhardt. Zij is Business Development Director van de Biotech Campus Delft. “Dat vond oprichter en sociaal ondernemer Jacques van Marken van het huidige DSM Delft eind negentiende eeuw al. Ook nu is samenwerking de basisgedachte achter de Biotech Campus Delft.”

Met het gereedkomen van het Beijerinck Center begin 2019 gaat de campus echt van start. Het Beijerinck Center is een volledig gerenoveerd gebouw met kantoor- en labruimte en vormt de centrale ontmoetingsplek voor de campus. Gerhardt: “De naam staat symbool voor de samenwerking tussen industrie en wetenschappers op het gebied van biotechnologie. Martinus Willem Beijerinck deed wetenschappelijke ontdekkingen in het fabriekslaboratorium en werd later de eerste hoogleraar microbiologie ter wereld.”

Innoveren draait om slim samenwerken

Het Beijerinck Center biedt ruimte aan bedrijven actief in de industriële (witte) biotechnologie. Gerhardt: “Zij krijgen niet alleen een laboratorium en kantoorruimte in dit gebouw, maar ook toegang tot het restaurant, de fitness en vergaderzalen. Nog veel belangrijker is de toegang tot het innovatie ecosysteem met mentoren van DSM, cursussen die we samen met de TU-Delft of hogescholen ontwikkelen, conferenties en netwerkevenementen. De biotech campus doet er alles aan om uitwisseling van kennis en talent te stimuleren, omdat innoveren in de 21e eeuw draait om slim samenwerken.”

Campus bewoners

Momenteel bevinden zich op de Biotech Campus Delft al verschillende bedrijven, actief in de biotechnologie; DSM Food Specialties, met daaraan gelieerd het DSM Biotechnologie Centrum (DBC), de Bioprocess Pilot Facility (BPF) en Centrient Pharmaceuticals. Bij DBC werken ruim 400 wetenschappers op alle gebieden van de industriële biotechnologie, van discovery tot genetica tot fermentatie, formulering en toepassing van bio-based ingrediënten. De BPF biedt op pilot plant-schaal een springplank voor proeven in de opschaling van reageerbuis naar fabriek.

Mix van bedrijven

Vanaf begin 2019 zal het aantal bedrijven toenemen. Het Beijerinck Center biedt ruimte aan twee joint ventures met DSM: Veramaris en Avansya. Daarnaast aan een twintigtal nieuwe, kleinere bedrijven. Gerhardt hoopt een mix van verschillende bedrijven aan te trekken op de campus.

Biotech start-ups, of deze nu vanuit de TU Delft of een andere universiteit komen, als spin-off vanuit DSM of een ander bedrijf, kunnen profiteren van een ecosysteem met kennis en een volledige infrastructuur. Zelf zijn zij voor de grotere bedrijven op de campus een bron van inspiratie en ondernemerschap. We kunnen met trots noemen dat de eerste biotech startups met interesse in de campus zich al hebben gemeld!

Opschalen groene processen

Het lokale MKB heeft vaak behoefte aan het ontwikkelen en opschalen van nieuwe, groenere processen, bijvoorbeeld door reststromen slimmer te verwerken. Toegang tot de technologie is niet altijd makkelijk. Het MKB kan slim innoveren op de campus, bijvoorbeeld met financiële ondersteuning van zogenaamde ‘fieldlab’ subsidies.

Een derde categorie campus-collega’s zijn grote internationale bedrijven. Zij komen af op de goede reputatie en het hoge kennisniveau van de bio-based industrie in Nederland en op de (al dan niet gesubsidieerde) samenwerkingsmogelijkheden in Europa. De Biotech campus Delft is uniek omdat het, zo dicht bij het centrum van Delft, ook ruimte biedt aan nieuwbouw van laboratoria, kantoren en fabrieken.

Tot slot is een ecosysteem niet compleet zonder dienstverleners die de andere bedrijven ondersteunen: contract research, adviesbureaus, loopbaancoaches en andere ondersteunende activiteiten.

Bijdrage aan circulaire economie

Gerhardt kan niet wachten tot het gonst van de nieuwe activiteiten, hoewel ze weet dat de opbouw van een nieuwe campus veel tijd kost. Maar, ze is ervan overtuigd dat de campus meerwaarde biedt aan start-ups, MKB en grote bedrijven die actief zijn op het gebied van industriële biotechnologie. “Voortbordurend op 150 jaar ervaring in academisch onderzoek en commercialisatie van bio-based producten, kunnen we in Delft een concrete bijdrage leveren aan de transitie naar een duurzame, circulaire economie!”

Meer informatie vind je op de op de website van de Biotech Campus Delft: www.biotechcampusdelft.com